Novel Product Targeting T-Cell and B-Cell Lymphomas in Combination with Doxorubicin

Study Details:

Species: Canines

Tumor: Dogs with T-Cell and B-Cell Lymphomas

For more information: Click Here or CONTACT DR. MICHELE STEFFEY (530-752-1393) FOR INCLUSION IN THE STUDY.

Purpose of the Study Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and ages. Lymphoma is a devastating disease that, when left untreated, will lead to death in weeks. There is no cure known to this disease. Current treatments involve the use of extensive chemotherapy and / or radiotherapy, resulting generally in an initial response followed by relapse, and eventually resistance. Further, these treatments may be associated with severe side effects affecting patient’s quality of life. Therefore, a more effective and safe treatment for canine lymphoma is urgently needed.

New treatments based on the use of tumor targeting Product (non-chemotherapeutic agents) have been developed and used for the treatment of lymphoma in humans achieving an improved treatment efficacy with survival extension and an improved quality of life while significantly reducing toxicity. These treatments have proven to be groundbreaking for humans.

This Product is designed specifically for dogs. This Product was shown to be safe in normal dogs and effective at depleting lymphoma cells in laboratory studies. This study proposes the use of this Product to obtain additional data about its safety and its Pharmacokinetic and Pharmacodynamic properties in dogs with lymphoma.